With $1B in VC cash, Intarcia is happy to stay out of the IPO scrum

Damian Garde

Therapeutics is rolling toward an FDA application with its long-acting diabetes treatment, but despite the ready availability of IPO for drug developers, the company is content to private for now.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS